Login to Your Account

Other Adjuvant Trials Ongoing

Genentech Buyout Price Looking Better on Avastin Adjuvant Miss

By Jennifer Boggs

Thursday, April 23, 2009
It looks like $95 per share was a pretty good deal after all for Genentech Inc. shareholders. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription